However, as standard risk MM is generally associated with a lower disease burden than high risk MM [38–40], one might speculate that NT-proBNP levels might be less frequently elevated and therefore a more robust marker of cardiovascular risk in the standard risk setting. The gene discussed is NPPB; the disease is Miyoshi myopathy.